Endocrine Testing Market Size To Reach $27.32 Billion By 2033

May 2026 | Report Format: Electronic (PDF)

Endocrine Testing Market Growth & Trends

The global endocrine testing market size is estimated to reach USD 27.32 billion by 2033, registering a CAGR of 8.48% from 2026 to 2033, according to a new report by Grand View Research, Inc. The growing prevalence of life style diseases such as obesity coupled with diabetes & thyroid among the adult as well as the geriatric population is driving the need for endocrine testing. The routine endocrine testing in individuals will help in overall maintenance of health and thus this awareness of better health is significantly contributing to the global endocrine testing market growth.

As per the statistics by WHO, more than 39 million children in 2020 who were under the age of 5 were overweight or obese. The sedentary life along with unhealthy diet choices have contributed to obesity as well as diabetes in the general population. This occurrence of diseased conditions has also prompted many researches into the metabolic functions and related hormonal disorders.

Funding from government and private organizations has also driven the scientific community. For instance, the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) by NIH drives many sponsored research programs towards improving health by better understanding of diseases. One such effort by NIDDK was the mid-atlantic symposium conducted in September 2022 for diabetes and obesity research. This will enable scientific knowledge exchange and interactions and allow collaboration at the regional level. Such initiatives will drive the understanding of endocrine function in the human body and will further enable the endocrine testing market growth.

The lack of awareness in underdeveloped and developing countries is anticipated to slow the growth of endocrine testing market. The developing health care settings and absence of reimbursement models restrain the individuals in these regions to undergo routine endocrine testing. However, with the growing consciousness of a healthy system during the COVID-19 pandemic is expected to upswing the testing frequency for these countries as well.

The outbreak of COVID-19 has created lucrative opportunities for the application of endocrine testing. COVID-19 infections cause a systemic disease that injures many organs. Therefore, these patients have many metabolic and hormonal disturbances that led to an increase in the number of endocrine research. For instance, in March 2021, Endocrine society members sanctioned USD 10 billion to support COVID-19 research to identify and understand the short and long-term COVID-19 effects on the endocrine system. Similarly, in September 2020, The American Diabetes Association invested USD 1 million to fund various research projects for investigating the link between diabetes and COVID-19. Thus, it will increase the demand and further boost market growth.

In addition, the limitation of movement and restrictions due to the lockdown encouraged the digital platform for medical consultation and at home sample collection services as well. The availability of point-of-care devices and kits for the detection of hormone levels at home is also driving the overall growth of endocrine testing market.

The market players are also expanding their regional presence due to various factors that are anticipated to grow the endocrine testing market. Collaboration, partnerships and global expansions are some of the business strategies by the key players to drive revenue generation. For instance, in February 2022 Laboratory Corporation of America Holdings (Labcorp) announced opening of a new laboratory in Indiana, U.S. The new diagnostics business in South Bend, Indiana will enhance the company’s services and make their offerings accessible to both patients as well as physicians in this region.

key Request a free sample copy or view report summary: Endocrine Testing Market Report

Endocrine Testing Market Report Highlights

By test type, the thyroid stimulating hormone (TSH) test segment accounted for the largest revenue share of 29.67% in 2025, due to the high prevalence of thyroid disorders, increasing routine health screening practices, and the widespread use of TSH assays as a first-line diagnostic tool for thyroid dysfunction assessment.
By technology, the immunoassay segment accounted for the largest revenue share in 2025, driven by its extensive use in routine hormone analysis, high-throughput laboratory workflows, and strong compatibility with automated diagnostic platforms.
BY end-use, the commercial laboratories segment accounted for the largest revenue share of 46.38% in 2025, driven by the growing shift toward centralized, high-throughput diagnostic testing and the increasing preference for outsourced laboratory services among healthcare providers.
North America endocrine testing market held the largest revenue share of over 39.66% in 2025 and is anticipated to maintain its position during the forecast period.